Pradaxa 150mg BiD administration is extended.

Pradaxa 150mg BiD administration is extended.

Antiphospholipid antibody syndrome is a risk factor for recurrent thrombosis in patients with unprovoked PE.

Extended use of anticoagulation can be considered and risk-benefit ratio needs to be regularly re-assessed (IC classification).

What should the doctor do?

Patient is referred to a cardiologist for further work up

Map: VTE_scenario_2 (467)
Node: 11042
Score:

OpenLabyrinth is an open source educational pathway system

Review your pathway

My measurements are quite often outside the desired range and I could ask my physician if I am a good candidate for the newer drugs (NOAC).
Treatment.
Treatment with VKA is started.
If I am to stay in the same anticoagulation regimen, I should adjust my dosage and regulate my diet according to my doctor’s advice.
Further coagulation diagnostics are performed.
Treatment.
Drop out of therapy early
I will ask a relative/friend, who also takes a NOAC on how to monitor the drug’s effectiveness.
Apixaban has a predictable-fixed effect and there is no need for routine testing of its efficacy.
Male 55 years old with paroxysmal AF.
I can be sure that the drug works fine, as long as I adhere to my previous diet low in vitamin K.
Pradaxa 150mg BiD administration is extended.

Reminder

empty_reminder_msg

FINISH

Time is up